SCHEMBL4237676

SCHEMBL4237676

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC45CCCC(CC4)N5C)cc3)cc2)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNLIP P16233 7/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PKM P14618 1/20 0.38
CHRM1 P11229 1/20 0.37
MCHR1 Q99705 2/20 0.36
F7 P08709 1/20 0.35
GCGR P47871 1/20 0.35
ATM Q13315 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MCHR2 Q969V1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742393 0.94 NPC1 (0.39) PNLIPNPC1RAB9ACASP3SENP7
SCHEMBL4236329 0.92 PKM (0.38) NPC1RAB9ACASP3SENP7MAPT
SCHEMBL4238833 0.92 PKM (0.38) NPC1RAB9AMAPTPKMMCHR1
SCHEMBL4237744 0.92 PKM (0.38) NPC1RAB9ACASP3SENP7MAPT
SCHEMBL4229247 0.91 MCHR1 (0.45) NPC1RAB9ASMN1; SMN2PKMMCHR1
SCHEMBL4233302 0.91 PKM (0.38) PNLIPMAPTPKMMCHR1KDM4E
SCHEMBL4239015 0.91 PKM (0.43) MAPTPKMMCHR1KDM4EMEN1
SCHEMBL4237367 0.91 MCHR1 (0.39) MAPTSMN1; SMN2PKMMCHR1MEN1
SCHEMBL4232426 0.89 MCHR1 (0.40) NPC1RAB9ACASP3SENP7MAPT
SCHEMBL4228934 0.89 PKM (0.38) NPC1RAB9ACASP3SENP7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PNLIP 1855/4885NPC1 2338/4885RAB9A 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.